Seeking Value: GSK’s Drug-Safety AI Strategy Connects Data With Outcomes
Summary
GSK is using AI and conventional automation to move drug-safety reports through its pharmacovigilance process with fewer repeated manual steps. GSK and Cognizant have pursued smaller automation projects, while a proposed system of specialized AI agents remains a longer-term plan; the article says human judgment is still important for decisions that require interpretation and regulatory expertise.Key Facts
- GSK receives drug-safety information through channels including email, paper mail, fax and data loggers.
- GSK says repeated data entry and handoffs can slow the routing of reports to specialists.
- GSK uses AI-based and conventional automation to classify incoming reports, set priorities and direct information to specialists.
- Structuring information when it arrives can help retain context for later checks and reviews.
- GSK’s established safety systems remain a source of truth for much of its information.
- Cognizant’s Mohammad Haque described a proposed platform spanning seven connected areas of drug-safety operations.
- Haque estimated that about 40 specialized AI agents could eventually support tasks across the drug-safety process.
- GSK and Cognizant have pursued narrower automation initiatives, while the coordinated agent system remains a longer-term plan.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
